Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Behandlungsrealität von Patienten mit metastasiertem Nierenzellkarzinom in Deutschland – Daten aus dem RCC-Register.

Goebell, P.-J., Müller, L., Hübner, A., Lück, A., Koska, M., Marschner, N., 2014.

oral presentation, DGU.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGU / Journal: -
TNK
2014
A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: Results from the FAMOUS study.

Goebell, P., Münch, A., Müller, L., Hurtz, H.-J., Koska, M., Busies, S., Marschner, N., 2014.

Urol Oncol 32, 362–370. doi:10.1016/j.urolonc.2013.09.009

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: Urologic Oncology
TNK
2014
Behandlungsrealität von Patienten mit metastasiertem Nierenzellkarzinom in Deutschland – Daten aus dem RCC-Register.

Eder E, Müller L, Hübner A, Koska M, Marschner N, Goebell P-J, 2014.

Oral presentation at Gemeinsame Tagung BUV/OEGU. 2014;(FV17).

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: Bayrische Urologenvereinigung / Journal: -
TNK
2014
Bendamustine-based first line therapy in chronic lymphocytic leukemia (CLL) in routine clinical practice: Interim analysis of the German non-interventional study Be-CeLL1st.

Bruch, H.-R., Aldaoud, A., Klausmann, M., Hansen, R., Losem, C., Frank, M., Straßl, L., Ruffert, K., 2014.

Haematologica 99 (suppl 1) (PB1504).

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: EHA / Journal: Haematologica
Be-Cell-1st
2014
Chemotherapy, targeted therapy and anti-hormonal therapy of elderly patients with breast cancer – data from the SENORA project.

Zahn, M.-O., Tesch, H., Köhler, A., Fietz, T., Münz, M., Kruggel, L., Jänicke, M., Marscher, N., 2014.

Oncol Res Treat 37 (suppl 5)(V374), 112. doi:10.1159/000368945

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TMK
2014
SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) / sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

Weikersthal, L.F. von, Goebell, P.J., de Santis, M. de, Lerchenmüller, C., Zimmermann, U., Bos, M.M.E.M., Freier, W., Schirrmacher-Memmel, S., Staehler, M.D., Pahernik, S., Los, M., Schenck, M., Flörcken, A., van Arkel, C.V., Hauswald, K., Indorf, M., Gottstein, D., Eichelberg, C., Michel, M.S., 2014.

Oncol Res Treat 37 (suppl 5)(V28), 5. doi:10.1159/000368945

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
RCC-SWITCH
2014
Prognostic factors for overall survival in patients with advanced NSCLC – data from the clinical registry on lung cancer (TLK).

von Verschuer, U., Tessen, H.W., Eggert, J., Neise, M., Frank, M., Jänicke, M., Spring, L., Marschner, N., 2014.

Oncol Res Treat 37 (suppl 5)(V701), 227. doi:10.1159/000368945

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLK
2014
Effectiveness of treatments for tumor-(therapy-) associated anemia in routine practice – data from the clinical tumor anemia registry (TAR).

Steinmetz, T., Köhler, A., Groschek, M., Koenigsmann, M., Vogt, M., Frank, M., Jänicke, M., 2014.

Oncol ResTreat 37 (suppl 5)(P534), 172. doi:10.1159/000368945

Abstract

Download

Indikation: Supportive Therapy, Supportivtherapie / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TAR
2014
Real-life treatment and outcome data for patients with advanced NSCLC receiving treatments containing bevacizumab – data from the clinical registry on lung cancer (TLK).

Steffens, C.-C., Tessen, H.W., Losem, C., Münz, M., Jänicke, M., Spring, L., Marschner, N., 2014.

Oncol Res Treat 37 (suppl 5)(P217), 64. doi:10.1159/000368945

Abstract

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLK
2014
Effectiveness of bevacizumab beyond progression in patients with metastatic colorectal cancer – data from the clinical TKK registry.

Schnell, R., Musch, R., Broszeit-Luft, S., Harde, J., Kopfmann, S., Jänicke, M., Marschner, N., 2014.

Oncol Res Treat 37(Suppl.5)(V332), 101. doi:10.1159/000368945

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TKK
2014